Navigation Links
ABR-Affinity BioReagents to Exhibit at the Society for Biomolecular Sciences in St. Louis, April 6 - 10, 2008
Date:4/2/2008

DENVER and GOLDEN, Colo., April 2, 2008 /PRNewswire/ -- ABR-Affinity BioReagents, a leading global antibody manufacturer, announced today that it will exhibit for the first time at the 14th Annual Conference and Exhibition of the Society for Biomolecular Sciences (SBS) in St. Louis, April 6 - 10, 2008.

"We are extremely pleased to support the advancement of the science of drug discovery by exhibiting at the SBS meeting, especially as it is a non-profit forum. This is our first in what I foresee as a multiple year commitment to supporting this cutting edge area of basic and applied pharmaceutical research," said Ken Wilczek, President of ABR. "It is truly a privilege to be involved with these top-level, dedicated institutions and talented individuals in the furtherance of innovative drug discovery research that could lead to potentially life-saving therapies," continued Mr. Wilczek. ABR-Affinity BioReagents' high quality portfolio of monoclonal and polyclonal antibodies, recombinant proteins, siRNA and custom antibody and peptide production services are already in use by every major research institution, government agency, university, and pharmaceutical company in the world today.

"Feedback from leading researchers in the areas of cancer biology and disease research, especially arthritis and inflammation, is invaluable to us in determining strategic direction. The international character of this audience will enable ABR to collaborate on a meaningful level with the most influential scientists in the world," noted Mr. Wilczek. ABR-Affinity BioReagents will be located at booth #220.

About ABR-Affinity BioReagents

Founded in 1989 with world headquarters in Golden, Colorado, ABR-Affinity BioReagents is a world leader in the manufacture and distribution of monoclonal and polyclonal antibodies, kits, recombinant proteins, siRNA, and custom antibody production services, known as Antibody on Demand(R).

With more than 35,000 antibodies focused in 43 research areas, ABR offers a unique value proposition in the life science industry -- research antibodies that are 100% quality guaranteed or your money back -- with no questions asked.

Utilizing a distribution network encompassing over 55 nations, ABR products are readily available in every research market on the globe. Products are available directly from ABR in the United States, as well as through an exclusive distribution partnership with Fisher Scientific, a division of Thermo Fisher Scientific.

For additional information about ABR-Affinity BioReagents, contact Leslie Martin with ABR media relations at 1-800-527-4535.


'/>"/>
SOURCE ABR-Affinity BioReagents
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ABR-Affinity BioReagents Finalizes Agreement for Distribution of Osenses Antibodies in the U.S., Canada and Europe
2. ABR-Affinity BioReagents to Exhibit at ASCB in Washington D.C., December 1 - 5, 2007
3. ABR-Affinity BioReagents Announces Agreements for U.S. Distribution of Research Antibodies
4. Corgenix to Exhibit AspirinWorks(R) Test at ACC 2008 Meeting in Chicago
5. Atherotech to Exhibit the VAP Test (R) at ACC 2008 Meeting in Chicago
6. Biotechnology Leader to Exhibit at Upcoming Trade Show
7. BioInformatics, LLC Studies Trade Show Exhibition Strategies in the Life Science Market
8. West Michigan Science & Technology Initiative Seeks Exhibitors for Annual Life Science Showcase
9. Maryland Science Center Unveils Anatomical Exhibition, Body Worlds 2, on Saturday, February 2
10. Imaging Diagnostic Systems Exhibits at Major Middle East Health Conference
11. Kiwa Bio-Tech Products Group Holds a Fertilizer Products Exhibition in Hebei
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... /PRNewswire/ - The Fight Against Cancer Innovation Trust (FACIT) ... pleased to report that Fusion Pharmaceuticals Inc. (Fusion) has ... Johnson Innovation – JJDC, Inc. (JJDC) as the lead ... Biotechnology Partners, and Genesys Capital, as well as founding ... ...
(Date:2/23/2017)... Minn. , Feb. 23, 2017  Imanis ... new product line of oncolytic vaccinia viruses for ... Corporation as part of Genelux,s proprietary, vaccinia virus-based ... are excited to enter into a partnership with ... selected oncolytic vaccinia viruses for use in research," ...
(Date:2/23/2017)... ... 23, 2017 , ... Today, researchers can fast-track sample collection ... and/or other biomarkers or SNPs of interest) using one, easy-to-collect saliva sample. With ... relationship between insulin and other relevant biomarkers can be extensively studied through a ...
(Date:2/23/2017)... SAN DIEGO and SAN FRANCISCO ... , a privately-held regenerative medicine company, and Beyond Type ... living with type 1 diabetes, today announced a grant ... develop a functional cure for type 1 and other ... decade, ViaCyte has been developing innovative stem cell-derived cell ...
Breaking Biology Technology:
(Date:2/8/2017)... , Feb. 8, 2017 About Voice ... voice to match it against a stored voiceprint ... as pitch, cadence, and tone are compared to ... minimal hardware installation, as most PCs already have ... different transactions. Voice recognition biometrics are most likely ...
(Date:2/7/2017)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that the latest release of ... and award winning eClinical solution, is now available for ... a proven Software-as-a-Service (SaaS) clinical research technology platform that ... delivers an entire suite of eClinical tools to support ...
(Date:2/3/2017)... -- A new independent identity strategy consultancy firm announces ... Designed to fill a critical niche in technical and ... Mark Crego and Janice Kephart ... expertise that span federal governments, the 9/11 Commission, private ... expertise has a common theme born from a shared ...
Breaking Biology News(10 mins):